Evidence map›Paper›PMID 28331826›Full record

ReviewTranslational lung cancer research2017

Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.

Jian-Wei Gao, Stefania Rizzo, Li-Hong Ma, Xiang-Yu Qiu, Arne Warth, Nobuhiko Seki, Mizue Hasegawa, Jia-Wei Zou, Qian Li, Marco Femia and 3 more

Open access · hybridAbstract readReview
In one paragraph

Review in Translational lung cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 4 countries.

Jian-Wei GaoDepartment of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Stefania RizzoDepartment of Radiology, European Institute of Oncology, Milan, Italy.
Li-Hong MaDepartment of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Xiang-Yu QiuThe Research Institute of General Surgery, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Arne WarthThe Research Institute of General Surgery, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China;; Translational Lung Research Centre Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
Nobuhiko SekiDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
Mizue HasegawaDepartment of Diagnostic Radiology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan;; Department of Respiratory Medicine, Tokyo Women's Medical University, Yachiyo Medical Center, Tokyo, Japan.
Jia-Wei ZouDepartment of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Qian LiDepartment of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Marco FemiaUniversità degli studi di Milano, Postgraduation School in Radiodiagnostics, Milan, Italy.
Tang-Feng LvDepartment of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Yong SongDepartment of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
written on behalf of the AME Lung Cancer Collaborative Group
Nanjing General Hospital of Nanjing Military Command · CNUniversity of Milan · ITGerman Center for Lung Research · DESaitama International Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of pulmonary ground-glass opacity (GGO) lesions is increasing as a result of the widespread use of multislice spiral computed tomography (CT) and the low-dose CT screening for lung cancer detection. Besides benign lesions, GGOs can be a specific type of lung adenocarcinomas or their preinvasive lesions. Evaluation of pulmonary GGO and investigation of the correlation between CT imaging features and lung adenocarcinoma subtypes or driver genes can be helpful in confirming the diagnosis and in guiding the clinical management. Our review focuses on the pathologic characteristics of GGO detected at CT, involving histopathology and molecular pathology.

Indexed as

anaplastic lymphoma kinase gene (ALK)computed tomography (CT)driver genesepidermal growth factor receptor gene (EGFR)Ground-glass opacity (GGO)Kirsten rat sarcoma viral oncogene homolog (KRAS)pathology

Identifiers

PMID28331826
PMCPMC5344841
OpenAlexW2594032648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.